Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360º synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of primary biliary cholangitis
3.2.1.2 Increasing patient preference for non-invasive treatment
3.2.1.3 Growing number of research and development activities
3.2.1.4 Increasing advancement in diagnostic technologies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of curative treatment
3.2.2.2 Limited awareness among healthcare providers and patients
3.3 Growth potential analysis
3.4 Pricing analysis
3.5 Future market trends
3.6 Regulatory landscape
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug, 2021 - 2032 ($ Million)
5.1 Key trends
5.2 Ursodeoxycholic acid
5.3 Obeticholic acid
5.4 Other drugs
Chapter 6 Market Estimates and Forecast, By Use, 2021 - 2032 ($ Million)
6.1 Key trends
6.2 Human
6.3 Veterinary
Chapter 7 Market Estimates and Forecast, By Distribution channel, 2021 - 2032 ($ Million)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Drug store & retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 Arlak Biotech Pvt. Ltd
9.3 Cadila Pharmaceuticals
9.4 Drag Pharma
9.5 Gilead Sciences, Inc.
9.6 Intercept Pharmaceuticals, Inc.
9.7 Ipsen
9.8 Leeford Healthcare Limited
9.9 Lupin
9.10 Sun Pharmaceuticals Ltd.
9.11 Viatris, Inc. (Mylan N.V.)
9.12 Vivaldis
